Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9704 |
High Similarity |
NPD7266 |
Discontinued |
0.8039 |
Intermediate Similarity |
NPD1653 |
Approved |
0.8 |
Intermediate Similarity |
NPD6190 |
Approved |
0.7927 |
Intermediate Similarity |
NPD7074 |
Phase 3 |
0.7927 |
Intermediate Similarity |
NPD7472 |
Approved |
0.7866 |
Intermediate Similarity |
NPD7054 |
Approved |
0.7831 |
Intermediate Similarity |
NPD7685 |
Pre-registration |
0.7831 |
Intermediate Similarity |
NPD7251 |
Discontinued |
0.7805 |
Intermediate Similarity |
NPD7228 |
Approved |
0.7784 |
Intermediate Similarity |
NPD7808 |
Phase 3 |
0.7771 |
Intermediate Similarity |
NPD6797 |
Phase 2 |
0.7673 |
Intermediate Similarity |
NPD8455 |
Phase 2 |
0.7603 |
Intermediate Similarity |
NPD3027 |
Phase 3 |
0.7582 |
Intermediate Similarity |
NPD8166 |
Discontinued |
0.7471 |
Intermediate Similarity |
NPD4338 |
Clinical (unspecified phase) |
0.7469 |
Intermediate Similarity |
NPD4868 |
Clinical (unspecified phase) |
0.7456 |
Intermediate Similarity |
NPD7993 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD1612 |
Clinical (unspecified phase) |
0.745 |
Intermediate Similarity |
NPD1613 |
Approved |
0.7442 |
Intermediate Similarity |
NPD8055 |
Clinical (unspecified phase) |
0.7436 |
Intermediate Similarity |
NPD6143 |
Clinical (unspecified phase) |
0.7427 |
Intermediate Similarity |
NPD8312 |
Approved |
0.7427 |
Intermediate Similarity |
NPD8313 |
Approved |
0.7412 |
Intermediate Similarity |
NPD7240 |
Approved |
0.7381 |
Intermediate Similarity |
NPD3818 |
Discontinued |
0.7378 |
Intermediate Similarity |
NPD6234 |
Discontinued |
0.7337 |
Intermediate Similarity |
NPD7804 |
Clinical (unspecified phase) |
0.7317 |
Intermediate Similarity |
NPD4381 |
Clinical (unspecified phase) |
0.731 |
Intermediate Similarity |
NPD4379 |
Clinical (unspecified phase) |
0.729 |
Intermediate Similarity |
NPD6674 |
Discontinued |
0.7285 |
Intermediate Similarity |
NPD230 |
Phase 1 |
0.7284 |
Intermediate Similarity |
NPD37 |
Approved |
0.7262 |
Intermediate Similarity |
NPD6168 |
Clinical (unspecified phase) |
0.7262 |
Intermediate Similarity |
NPD6167 |
Clinical (unspecified phase) |
0.7262 |
Intermediate Similarity |
NPD6166 |
Phase 2 |
0.7256 |
Intermediate Similarity |
NPD4966 |
Approved |
0.7256 |
Intermediate Similarity |
NPD4967 |
Phase 2 |
0.7256 |
Intermediate Similarity |
NPD4965 |
Approved |
0.7216 |
Intermediate Similarity |
NPD8397 |
Clinical (unspecified phase) |
0.7181 |
Intermediate Similarity |
NPD1529 |
Clinical (unspecified phase) |
0.7172 |
Intermediate Similarity |
NPD1091 |
Approved |
0.7135 |
Intermediate Similarity |
NPD7879 |
Clinical (unspecified phase) |
0.7114 |
Intermediate Similarity |
NPD1530 |
Clinical (unspecified phase) |
0.711 |
Intermediate Similarity |
NPD6559 |
Discontinued |
0.7101 |
Intermediate Similarity |
NPD3022 |
Approved |
0.7101 |
Intermediate Similarity |
NPD3021 |
Approved |
0.7081 |
Intermediate Similarity |
NPD6980 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD4978 |
Clinical (unspecified phase) |
0.7078 |
Intermediate Similarity |
NPD7097 |
Phase 1 |
0.7073 |
Intermediate Similarity |
NPD1934 |
Approved |
0.7055 |
Intermediate Similarity |
NPD3705 |
Approved |
0.703 |
Intermediate Similarity |
NPD2393 |
Clinical (unspecified phase) |
0.7027 |
Intermediate Similarity |
NPD7680 |
Approved |
0.7025 |
Intermediate Similarity |
NPD4628 |
Phase 3 |
0.6995 |
Remote Similarity |
NPD7237 |
Clinical (unspecified phase) |
0.6994 |
Remote Similarity |
NPD3455 |
Phase 2 |
0.6982 |
Remote Similarity |
NPD7199 |
Phase 2 |
0.6982 |
Remote Similarity |
NPD8127 |
Discontinued |
0.6966 |
Remote Similarity |
NPD1357 |
Approved |
0.6951 |
Remote Similarity |
NPD4380 |
Phase 2 |
0.6943 |
Remote Similarity |
NPD2029 |
Clinical (unspecified phase) |
0.6936 |
Remote Similarity |
NPD5844 |
Phase 1 |
0.6928 |
Remote Similarity |
NPD1465 |
Phase 2 |
0.6918 |
Remote Similarity |
NPD5126 |
Approved |
0.6918 |
Remote Similarity |
NPD5125 |
Phase 3 |
0.6905 |
Remote Similarity |
NPD7075 |
Discontinued |
0.6898 |
Remote Similarity |
NPD8320 |
Phase 1 |
0.6898 |
Remote Similarity |
NPD8319 |
Approved |
0.6886 |
Remote Similarity |
NPD3817 |
Phase 2 |
0.6883 |
Remote Similarity |
NPD4060 |
Phase 1 |
0.6879 |
Remote Similarity |
NPD228 |
Approved |
0.6855 |
Remote Similarity |
NPD1652 |
Phase 2 |
0.6842 |
Remote Similarity |
NPD8151 |
Discontinued |
0.6839 |
Remote Similarity |
NPD4340 |
Discontinued |
0.6832 |
Remote Similarity |
NPD5058 |
Phase 3 |
0.6828 |
Remote Similarity |
NPD5536 |
Phase 2 |
0.6826 |
Remote Similarity |
NPD2801 |
Approved |
0.6826 |
Remote Similarity |
NPD2978 |
Approved |
0.6826 |
Remote Similarity |
NPD2977 |
Approved |
0.6818 |
Remote Similarity |
NPD6233 |
Phase 2 |
0.6816 |
Remote Similarity |
NPD8150 |
Discontinued |
0.6802 |
Remote Similarity |
NPD7184 |
Clinical (unspecified phase) |
0.6797 |
Remote Similarity |
NPD7095 |
Approved |
0.6788 |
Remote Similarity |
NPD7458 |
Discontinued |
0.6786 |
Remote Similarity |
NPD5402 |
Approved |
0.6782 |
Remote Similarity |
NPD3751 |
Discontinued |
0.6781 |
Remote Similarity |
NPD9545 |
Approved |
0.6776 |
Remote Similarity |
NPD2861 |
Phase 2 |
0.6766 |
Remote Similarity |
NPD7945 |
Clinical (unspecified phase) |
0.6761 |
Remote Similarity |
NPD969 |
Suspended |
0.6757 |
Remote Similarity |
NPD7700 |
Phase 2 |
0.6757 |
Remote Similarity |
NPD7699 |
Phase 2 |
0.6753 |
Remote Similarity |
NPD3764 |
Approved |
0.6748 |
Remote Similarity |
NPD4160 |
Clinical (unspecified phase) |
0.6746 |
Remote Similarity |
NPD3882 |
Suspended |
0.6732 |
Remote Similarity |
NPD4908 |
Phase 1 |
0.6731 |
Remote Similarity |
NPD5124 |
Phase 1 |
0.6731 |
Remote Similarity |
NPD5123 |
Clinical (unspecified phase) |
0.6726 |
Remote Similarity |
NPD7096 |
Clinical (unspecified phase) |
0.6726 |
Remote Similarity |
NPD7819 |
Suspended |
0.6714 |
Remote Similarity |
NPD1358 |
Approved |
0.6713 |
Remote Similarity |
NPD7843 |
Approved |
0.6688 |
Remote Similarity |
NPD6653 |
Approved |
0.6688 |
Remote Similarity |
NPD5314 |
Approved |
0.6687 |
Remote Similarity |
NPD1511 |
Approved |
0.6685 |
Remote Similarity |
NPD7549 |
Discontinued |
0.6684 |
Remote Similarity |
NPD7783 |
Phase 2 |
0.6684 |
Remote Similarity |
NPD7782 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3062 |
Approved |
0.6667 |
Remote Similarity |
NPD3619 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD3059 |
Approved |
0.6667 |
Remote Similarity |
NPD7966 |
Clinical (unspecified phase) |
0.6667 |
Remote Similarity |
NPD5403 |
Approved |
0.6667 |
Remote Similarity |
NPD7435 |
Discontinued |
0.6667 |
Remote Similarity |
NPD2935 |
Discontinued |
0.6667 |
Remote Similarity |
NPD3061 |
Approved |
0.6667 |
Remote Similarity |
NPD3620 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD5736 |
Approved |
0.6667 |
Remote Similarity |
NPD9269 |
Phase 2 |
0.6667 |
Remote Similarity |
NPD5283 |
Phase 1 |
0.6647 |
Remote Similarity |
NPD6232 |
Discontinued |
0.6647 |
Remote Similarity |
NPD3787 |
Discontinued |
0.6646 |
Remote Similarity |
NPD4538 |
Approved |
0.6646 |
Remote Similarity |
NPD4537 |
Clinical (unspecified phase) |
0.6646 |
Remote Similarity |
NPD5698 |
Clinical (unspecified phase) |
0.6646 |
Remote Similarity |
NPD4536 |
Approved |
0.6646 |
Remote Similarity |
NPD8389 |
Clinical (unspecified phase) |
0.6645 |
Remote Similarity |
NPD6798 |
Discontinued |
0.6645 |
Remote Similarity |
NPD6859 |
Clinical (unspecified phase) |
0.6645 |
Remote Similarity |
NPD4907 |
Clinical (unspecified phase) |
0.6645 |
Remote Similarity |
NPD3094 |
Phase 2 |
0.6644 |
Remote Similarity |
NPD3496 |
Discontinued |
0.6629 |
Remote Similarity |
NPD7473 |
Discontinued |
0.6627 |
Remote Similarity |
NPD3687 |
Approved |
0.6627 |
Remote Similarity |
NPD3686 |
Approved |
0.6625 |
Remote Similarity |
NPD5762 |
Approved |
0.6625 |
Remote Similarity |
NPD5763 |
Approved |
0.6624 |
Remote Similarity |
NPD1933 |
Approved |
0.6624 |
Remote Similarity |
NPD6355 |
Discontinued |
0.6623 |
Remote Similarity |
NPD2982 |
Phase 2 |
0.6623 |
Remote Similarity |
NPD2983 |
Phase 2 |
0.6611 |
Remote Similarity |
NPD7090 |
Clinical (unspecified phase) |
0.6608 |
Remote Similarity |
NPD7975 |
Clinical (unspecified phase) |
0.6607 |
Remote Similarity |
NPD6386 |
Approved |
0.6607 |
Remote Similarity |
NPD6385 |
Approved |
0.6606 |
Remote Similarity |
NPD7314 |
Clinical (unspecified phase) |
0.6606 |
Remote Similarity |
NPD1512 |
Approved |
0.66 |
Remote Similarity |
NPD422 |
Phase 1 |
0.6595 |
Remote Similarity |
NPD6534 |
Approved |
0.6595 |
Remote Similarity |
NPD6535 |
Approved |
0.6593 |
Remote Similarity |
NPD6842 |
Approved |
0.6593 |
Remote Similarity |
NPD6841 |
Approved |
0.6593 |
Remote Similarity |
NPD6843 |
Phase 3 |
0.6579 |
Remote Similarity |
NPD7697 |
Approved |
0.6579 |
Remote Similarity |
NPD7698 |
Approved |
0.6579 |
Remote Similarity |
NPD7696 |
Phase 3 |
0.6577 |
Remote Similarity |
NPD9384 |
Approved |
0.6577 |
Remote Similarity |
NPD9381 |
Approved |
0.6575 |
Remote Similarity |
NPD7157 |
Approved |
0.6568 |
Remote Similarity |
NPD6801 |
Discontinued |
0.6562 |
Remote Similarity |
NPD9570 |
Approved |
0.6561 |
Remote Similarity |
NPD943 |
Approved |
0.6561 |
Remote Similarity |
NPD1558 |
Phase 1 |
0.6561 |
Remote Similarity |
NPD826 |
Approved |
0.6561 |
Remote Similarity |
NPD825 |
Approved |
0.6558 |
Remote Similarity |
NPD9494 |
Approved |
0.6558 |
Remote Similarity |
NPD3018 |
Phase 2 |
0.6556 |
Remote Similarity |
NPD2981 |
Phase 2 |
0.6554 |
Remote Similarity |
NPD8470 |
Clinical (unspecified phase) |
0.655 |
Remote Similarity |
NPD7768 |
Phase 2 |
0.6546 |
Remote Similarity |
NPD7875 |
Clinical (unspecified phase) |
0.6546 |
Remote Similarity |
NPD7874 |
Approved |
0.6545 |
Remote Similarity |
NPD7004 |
Clinical (unspecified phase) |
0.6545 |
Remote Similarity |
NPD7422 |
Clinical (unspecified phase) |
0.6545 |
Remote Similarity |
NPD5401 |
Approved |
0.6543 |
Remote Similarity |
NPD3060 |
Approved |
0.6543 |
Remote Similarity |
NPD7421 |
Clinical (unspecified phase) |
0.6536 |
Remote Similarity |
NPD7039 |
Approved |
0.6536 |
Remote Similarity |
NPD7038 |
Approved |
0.6532 |
Remote Similarity |
NPD5494 |
Approved |
0.6528 |
Remote Similarity |
NPD7701 |
Phase 2 |
0.6526 |
Remote Similarity |
NPD6823 |
Phase 2 |
0.6525 |
Remote Similarity |
NPD3134 |
Approved |
0.6519 |
Remote Similarity |
NPD2934 |
Approved |
0.6519 |
Remote Similarity |
NPD2933 |
Approved |
0.6513 |
Remote Similarity |
NPD9622 |
Approved |
0.6509 |
Remote Similarity |
NPD7411 |
Suspended |
0.6508 |
Remote Similarity |
NPD6778 |
Approved |
0.6508 |
Remote Similarity |
NPD6779 |
Approved |
0.6508 |
Remote Similarity |
NPD6780 |
Approved |
0.6508 |
Remote Similarity |
NPD6782 |
Approved |
0.6508 |
Remote Similarity |
NPD6777 |
Approved |
0.6508 |
Remote Similarity |
NPD6781 |
Approved |
0.6508 |
Remote Similarity |
NPD6776 |
Approved |
0.6503 |
Remote Similarity |
NPD4110 |
Phase 3 |
0.6503 |
Remote Similarity |
NPD3750 |
Approved |
0.6503 |
Remote Similarity |
NPD1878 |
Clinical (unspecified phase) |
0.6503 |
Remote Similarity |
NPD6398 |
Clinical (unspecified phase) |
0.6503 |
Remote Similarity |
NPD4109 |
Clinical (unspecified phase) |
0.65
|
Remote Similarity |
NPD5588 |
Approved |